Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

14
Japan, EU, Canada and industry groups oppose proposed U.S. duties on imported cars

1h japantimes.co.jp
WASHINGTON – Japan, the European Union and Canada on Thursday expressed opposition to U.S. President Donald Trump’s proposal of additional tariffs of up to 25 percent on imported cars and parts, insisting that such imports from the three allies pose no threat to U.S. national security.
GM.WS.A TM GM.WS.B GM.WS.C 7203 TYT GM GM.WSB TOYOF

17
Wall Street dips on weak earnings, renewed trade jitters

2h moneycontrol
US stocks slipped on Thursday after earnings disappointed and trade jitters intensified on fears that the European Union could slap retaliatory tariffs on goods imported from the United States.
IBM FOX CCV CMCSA CCZ CCV.CL GM.WS.A GM.WS.B GM.WS.C TRI GM GM.WSB FOXA CMCSK

14
EU, Mexico automakers blast Trump auto tariff plan

2h malaymail
WASHINGTON, July 20 ― The Trump administration yesterday came under withering criticism from automakers, foreign governments and others as officials consider imposing tariffs of up to 25 per cent on imported cars and parts, a levy that could hike vehicle costs, hurting auto sales and industry jobs.
VLKAF GM.WS.A TM GM.WS.B GM.WS.C 7203 TYT GM GM.WSB TOYOF

17
Wall Street dips on weak earnings, renewed trade jitters

4h malaymail
NEW YORK, July 20 ― US stocks slipped yesterday after earnings disappointed and trade jitters intensified on fears that the European Union could slap retaliatory tariffs on goods imported from the United States.
IBM FOX CCV CMCSA CCZ CCV.CL GM.WS.A GM.WS.B GM.WS.C TRI GM GM.WSB FOXA CMCSK

17
U.S. stocks fall on sour earnings, trade fears

5h theedgemarkets
NEW YORK (July 20): U.S. stocks dropped on Thursday after earnings disappointed and trade jitters escalated over worries that the European Union could slap retaliatory tariffs on goods imported from the United States.
IBM FOX CCV CMCSA CCZ CCV.CL GM.WS.A GM.WS.B GM.WS.C TRI GM GM.WSB FOXA CMCSK

22
Time for Investors to Take Advantage of a Bargain in Ford Stock

5h investorplace
Ford (NYSE:F) has lost 10% of its value over the last month. This leaves many asking the question, “Why is Ford stock so low?” Automakers face continuing struggles on many fronts. The economy, interest rates, labor issues, supply issues and material costs stand as many factors that affect the stock price of Ford.
F TM GM.WS.A GM.WS.B GM.WS.C GM FCAU GM.WSB HMC

14
Commentary: If a Harley-Davidson motorcycle isn't 'made in America’, is it still a Harley-Davidson? - Channel NewsAsia

5h channelnewsasia
US President Donald trump may be pursuing his "America First" agenda putting higher tariffs on foreign products to prioritise domestic ones. But whether a product is local or foreign made won't stop American consumers from buying some, says one observer
GM.WS.A GM.WS.B GM.WS.C GM GM.WSB

63
Positive Surprises Tracking Above Historical Levels

7h zacks
There are two aspects to every quarterly reporting cycle that inform our judgement as to how positive or otherwise the overall picture emerging from the earnings season actually is. First, the growth rates (earnings and revenues), positive surprises and how these (growth rates/surprises) compare to historical periods. Second, how analysts are changing their estimates after seeing the earnings releases and management commentary.
WFC WFCNP WFC.WS BAC WFC.PRL WFC.PRJ BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO GM.WS.A WFC.PRN GM.WS.B GM.WS.C WFC.PRY GM WFC.PRX GM.WSB WFC.PRW WFC.PRV

14
Say Allo App Adds M. David Lewis, MD to Advisory Board - JustSayAllo.com

8h accesswire
Dr. Lewis is the Founder and Director of Successful Drug Treatment Programs for the NBA, NHL and MLS, and a Nationally Respected Substance Abuse Expert and Medical Professional
GM.WS.A GM.WS.B GM.WS.C ABCO GM GM.WSB

18
Elevate Credit (ELVT) and BioTelemetry (BEAT) Are Aggressive Growth Stocks

8h zacks
Brian Bolan is the aggressive growth stock strategist here at Zacks Investment Research and he loves talking about growth stocks. Today he found a stock that has a growth style score and a value style score of A – something that he doesn’t often have. That stock is Elevate Credit (ELVT - Free Report) , which also happens to the be a Zacks Rank #1 (Strong Buy). Brian likes the momentum the stock has seen following the most recent beat and notes that the big bank earnings are already out and the sector looks fine.
WFC WFCNP WFC.WS ELVT WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO GM.WS.A WFC.PRN GM.WS.B GM.WS.C WFC.PRY GM WFC.PRX GM.WSB WFC.PRW WFC.PRV BEAT

34
Wall St falls as Trump repeats European car import tariffs threat

8h nbr.co.nz
Stocks on Wall Street declined as a round of lukewarm corporate earnings reports and renewed trade tensions weighed on sentiment.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO GM.WS.A WFC.PRN GM.WS.B GM.WS.C WFC.PRY GM WFC.PRX GM.WSB WFC.PRW WFC.PRV DIS

31
Johnson & Johnson and General Motors: Growth and Income Stocks

8h zacks
Johnson & Johnson (JNJ - Free Report) currently holding a Zacks Rank #3 (Hold) reported earnings on July 17th where they beat both the Zacks consensus earnings and revenue estimates for the second consecutive quarter. The company saw sales growth in both the Medical Device and Pharmaceutical segments.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO JNJ GM.WS.A WFC.PRN GM.WS.B GM.WS.C GM WFC.PRY WFC.PRX GM.WSB WFC.PRW WFC.PRV

14
The Latest: Apple, Boeing sign Trump's job training pledge

8h nzherald.co.nz
Apple and Boeing are among the companies that are committing to President Donald Trump to provide increased training to their workers.
HD LMT GM.WS.A GM.WS.B GM.WS.C GM GM.WSB

38
Upcoming Earnings: GE Reports Friday Morning, Turnaround And Restructuring Rolls On

10h seekingalpha
There's no denying that General Electric (GE) has had a tough go over the past several years amid a long-running restructuring and turnaround effort. The company has been more vocal lately about all the steps it's taking as well as the fact that this turnaround is going to take time. So, investors might just be hoping for no surprises when GE reports earnings before market open on Friday, July 20.
BHI GEC GE GM.WS.A XOM GM.WS.B BHGE GM.WS.C GNE GM GM.WSB

14
Trump pushing job training as employers search for workers

10h nzherald.co.nz
WASHINGTON (AP) — President Donald Trump is pressing U.S. companies and trade associations to bolster their job training opportunities as employers search for qualified skilled workers to fill vacancies.
HD GM.WS.A GM.WS.B GM.WS.C GM GM.WSB

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 37045V118